Current understandings on the immunology of leishmaniasis and recent developments in prevention and treatment

British Medical Bulletin

Volumn 75-76, Issue 1, 2005, Pages 115-130

  Roberts, M T M ^a,b  

^a WORCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Leishmaniasis; Prevention; Review; Treatment; Vaccines

Indexed keywords

AMPHOTERICIN; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ANTIPROTOZOAL AGENT; ANTIRETROVIRUS AGENT; BCG VACCINE; CYTOKINE; DELTAMETHRIN; DNA VACCINE; FLUCONAZOLE; GAMMA INTERFERON; IMIQUIMOD; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4 ANTIBODY; LEISHMANIA VACCINE; MEGLUMINE; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; PROTOZOAL PROTEIN; PROTOZOON ANTIBODY; RECOMBINANT PROTEIN; SAPONIN; STIBOGLUCONATE SODIUM; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADJUVANT THERAPY; AGGLUTINATION TEST; BIOLOGICAL MODEL; BIOPSY; CD4+ T LYMPHOCYTE; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC TEST; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHEMA; GOLD STANDARD; HEART ARRHYTHMIA; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOTHERAPY; INCIDENCE; INFECTION PREVENTION; KIDNEY FAILURE; LEISHMANIA DONOVANI; LEISHMANIA INFANTUM; LEISHMANIA MAJOR; LEISHMANIASIS; LIVER DYSFUNCTION; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PAIN; PANCREATITIS; PARASITE; PARASITOLOGY; PRIORITY JOURNAL; PROTOZOAL GENETICS; QT PROLONGATION; REVIEW; SKIN LEISHMANIASIS; TH2 CELL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; URINALYSIS; VECTOR CONTROL; VIRUS VECTOR; VISCERA; VISCERAL LEISHMANIASIS; VOMITING; WORLD HEALTH ORGANIZATION;

ANIMALS; DISEASE RESERVOIRS; DISEASE VECTORS; FORECASTING; HUMANS; IMMUNE TOLERANCE; LEISHMANIASIS; MICE; VACCINES, DNA;

EID: 33750913168     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldl003     Document Type: Review

References (79)

1. Hommel M. Visceral leishmaniasis: biology of the parasite. J Infect 1999;39:101-11.
2. Gillespie RD, Mbow ML, Titus RG. The immunomodulatory factors of bloodfeeding arthropod saliva. Parasite Immunol 2000;22:319-31.
3. WHO. The World Health Report 197-97 [online], 2002; www.who.int.htm.
4. Seaman J, Mercer AJ, Sondorp E. The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol 1996;25:862-71.
5. Cruz I, Morales MA, Noguer I, Rodriguez A, Alvar J. Leishmania in discarded syringes from intravenous drug users. Lancet 2002;359:1124-5.
6. Blackwell JM. Genetic susceptibility to leishmanial infections: studies in mice and man. Parasitology 1996;112 Suppl:S67-74.
7. Boelaert M, Rijal S, Regmi S et al. A comparative study of the effectiveness of diagnostic tests for visceral leishmaniasis. Am J Trop Med Hyg 2004;70:72-7.
8. Zijlstra EE, Ali MS, el-Hassan AM et al. Kala-azar: a comparative study of parasitological methods and the direct agglutination test in diagnosis. Trans R Soc Trop Med Hyg 1992;86:505-7.
9. De Doncker S, Hutse V, Abdellati S et al. A new PCR-ELISA for diagnosis of visceral leishmaniasis in blood of HIV-negative subjects. Trans R Soc Trop Med Hyg 2005;99:25-31.
10. Wang ZE, Reiner SL, Zheng S, Dalton DK, Locksley RM. CD4+ effector cells default to the Th2 pathway in interferon gamma-deficient mice infected with Leishmania major. J Exp Med 1994;179:1367-71.
11. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1988;168:1675-84.
12. Scharton TM, Scott P. Natural killer cells are a source of interferon that drives differentiation of CD4+ T cell subsets and induces early resistance to Leishmania major in mice. J Exp Med 1993;178:567.
13. Scott P. IFN-gamma modulates the early development of Th1 and Th2 responses in a murine model of cutaneous leishmaniasis. J Immunol 1991;147:3149-55.
14. Kopf M, Brombacher F, Kohler G et al. IL-4-deficient Balb/c mice resist infection with Leishmania major. J Exp Med 1996;184:1127-36.
15. Julia V, Rassoulzadegan M, Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen. Science 1996;274:421-3.
16. Mattner F, Magram J, Ferrante J et al. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response. Eur J Immunol 1996;26:1553-9.
17. Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med 1993;177:1505-9.
18. von Stebut E, Belkaid Y, Jakob T, Sacks DL, Udey MC. Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J Exp Med 1998;188:1547-52.
19. Noben-Trauth N, Kropf P, Muller I. Susceptibility to Leishmania major infection in interleukin-4-deficient mice. Science 1996;271:987-90.
20. Matthews DJ, Emson CL, McKenzie GJ, Jolin HE, Blackwell JM, McKenzie AN. IL-13 is a susceptibility factor for Leishmania major infection. J Immunol 2000;164:1458-62.
21. Noben-Trauth N, Lira R, Nagase H, Paul WE, Sacks DL. The relative contribution of IL-4 receptor signaling and IL-10 to susceptibility to Leishmania major. J Immunol 2003;170:5152-8.
22. Belkaid Y, Von Stebut E, Mendez S et al. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 2002;168:3992-4000.
23. Belkaid Y, Hoffmann K, Mendez S et al. The role of Interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med 2001;194:1497-1506.
24. Belkaid Y, Piccirillo CA, Mendez S, Shevach EM, Sacks DL. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002;420:502-7.
25. McGuirk P, Mills KH. Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol 2002;23:450-5.
26. Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001;166:1141-7.
27. Kima PE, Constant SL, Hannum L et al. Internalization of Leishmania mexicana complex amastigotes via the Fc receptor is required to sustain infection in murine cutaneous leishmaniasis. J Exp Med 2000;191:1063-8.
28. Muller I, Pedrazzini T, Kropf P, Louis J, Milon G. Establishment of resistance to Leishmania major infection in susceptible BALB/c mice requires parasite-specific CD8+ T cells. Int Immunol 1991;3:587-97.
29. Huang FP, Xu D, Esfandiari EO, Sands W, Wei XQ, Liew FY. Mice defective in Fas are highly susceptible to Leishmania major infection despite elevated IL-12 synthesis, strong Th1 responses, and enhanced nitric oxide production. J Immunol 1998;160:4143-7.
30. Kemp M, Hey AS, Kurtzhals JA et al. Dichotomy of the human T cell response to Leishmania antigens. I. Th1-like response to Leishmania major promastigote antigens in individuals recovered from cutaneous leishmaniasis. Clin Exp Immunol 1994;96:410-5.
31. Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, Kharazmi A. Comparison of the immune profile of nonhealing cutaneous Leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun 2000;68:1760-4.
32. Louzir H, Melby PC, Ben Salah A et al. Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. J Infect Dis 1998;177:1687-95.
33. Convit J, Ulrich M, Fernandez CT et al. The clinical and immunological spectrum of American cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 1993;87:444-8.
34. Ghalib HW, Piuvezam MR, Skeiky YA et al. Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 1993;92:324-9.
35. Karp CL, el-Safi SH, Wynn TA et al. In vivo cytokine profiles in patients with kala-azar. Marked elevation of both interleukin-10 and interferon-gamma. J Clin Invest 1993;91:1644-8.
36. Kenney RT, Sacks DL, Gam AA, Murray HW, Sundar S. Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis 1998;177:815-8.
37. Sundar S, Reed SG, Sharma S, Mehrotra A, Murray HW. Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg 1997;56:522-5.
38. Babaloo Z, Kaye PM, Eslami MB. Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines. Trans R Soc Trop Med Hyg 2001;95:85-8.
39. Kemp K, Kemp M, Kharazmi A et al. Leishmania-specific T cells expressing interferon-gamma (IFN-gamma) and IL-10 upon activation are expanded in individuals cured of visceral leishmaniasis. Clin Exp Immunol 1999;116:500-4.
40. Karplus TM, Jeronimo SM, Chang H et al. Association between the tumor necrosis factor locus and the clinical outcome of Leishmania chagasi infection. Infect Immun 2002;70:6919-25.
41. Mohamed HS, Ibrahim ME, Miller EN et al. Genetic susceptibility to visceral leishmaniasis in The Sudan: linkage and association with IL4 and IFNGR1. Genes Immun 2003;4:351-5.
42. Bern C, Joshi AB, Jha SN et al. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg 2000;63:184-8.
43. Tayeh A, Jalouk L, Cairncross S. Twenty years of cutaneous leishmaniasis in Aleppo, Syria. Trans R Soc Trop Med Hyg 1997;91:657-9.
44. Maroli M, Mizzon V, Siragusa C, D'Oorazi A, Gradoni L. Evidence for an impact on the incidence of canine leishmaniasis by the mass use of deltamethrin-impregnated dog collars in southern Italy. Med Vet Entomol 2001;15:358-63.
45. Reithinger R, Coleman PG, Alexander B, Vieira EP, Assis G, Davies CR. Are insecticide-impregnated dog collars a feasible alternative to dog culling as a strategy for controlling canine visceral leishmaniasis in Brazil? Int J Parasitol 2004;34:55-62.
46. Modabber F. Experiences with vaccines against cutaneous leishmaniasis: of men and mice. Parasitology 1989;98(Suppl):S49-60.
47. Heyneman D. Immunology of leishmaniasis. Bull World Health Organ 1971;44:499-514.
48. Lemma A, Cole L. Leishmania enriettii: radiation effects and evaluation of radio-attenuated organisms for vaccination. Exp Parasitol 1974;35:161-9.
49. Streit JA, Recker TJ, Filho FG, Beverley SM, Wilson ME. Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms. J Immunol 2001;166:1921-9.
50. Sharifi I, FeKri AR, Aflatonian MR et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998;351:1540-3.
51. Mohebali M, Khamesipour A, Mobedi I, Zarei Z, Hashemi-Fesharki R. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran. Vaccine 2004;22:4097-100.
52. Lemesre JL, Holzmuller P, Cavaleyra M, Goncalves RB, Hottin G, Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine 2005;23:2825-40.
53. Fujiwara RT, Vale AM, Franca da Silva JC et al. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet Res 2005;36:827-38.
54. Saraiva EM, de Figueiredo Barbosa A, Santos FN et al. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine 2006;24:2423-31.
55. Spitzer N, Jardim A, Lippert D, Olafson RW. Long-term protection of mice against Leishmania major with a synthetic peptide vaccine. Vaccine 1999;17:1298-300.
56. Wolff JA, Malone RW, Williams P et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-1468.
57. Gurunathan S, Sacks D, Brown D et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers immunity to mice infected with Leishmania major. J Exp Med 1997;186:1137-47.
58. Gurunathan S, Prussin C, Sacks D, Seder R. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 1998;4:1409-15.
59. Akbari O, Panjwani N, Garcia S, Tascon R, Lowrie D, Stockinger B. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J Exp Med 1999;189:169-78.
60. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-12.
61. Zaph C, Uzonna J, Beverley SM, Scott P. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat Med 2004;10:104-10.
62. Stober CB, Lange UG, Roberts MT, Alcami A, Blackwell JM. IL-10 from regulatory T cells determines vaccine efficacy in murine Leishmania major infection. J Immunol 2005;175:2517-24.
63. Levick MP, Blackwell JM, Connor V et al. An expressed sequence tag analysis of a full-length, spliced-leader cDNA library from Leishmania major promastigotes. Mol Biochem Parasitol 1996;76:345-8.
64. Morris RV, Shoemaker CB, David JR, Lanzaro GC, Titus RG. Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J Immunol 2001;167:5226-30.
65. Ivens AC, Peacock CS, Worthey EA et al. The genome of the kinetoplastid parasite, Leishmania major. Science 2005;309:436-42.
66. Stober CB, Lange UG, Roberts MT et al. From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine 2005;24:2602-16.
67. Rafati S, Nakhaee A, Taheri T et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 2005;23:3716-25.
68. Jha TK, Olliaro P, Thakur CP et al. Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ 1998;316:1200-5.
69. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002;346:891-5.
70. Arana BA, Navin TR, Arana FE, Berman JD, Rosenkaimer F. Efficacy of a short course (10 days) of high-dose meglumine antimonate with or without interferon-gamma in treating cutaneous leishmaniasis in Guatemala. Clin Infect Dis 1994;18:381-4.
71. Arevalo I, Ward B, Miller R et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001;33:1847-51.
72. Hepburn NC, Siddique I, Howie AF, Beckett GJ, Hayes PC. Hepatotoxicity of sodium stibogluconate in leishmaniasis. Lancet 1993;342:238-9.
73. Gasser RA Jr, Magill AJ, Oster CN, Franke ED, Grogl M, Berman JD. Pancreatitis induced by pentavalent antimonial agents during treatment of leishmaniasis. Clin Infect Dis 1994;18:83-90.
74. Hepburn NC, Nolan J, Fenn L et al. Cardiac effects of sodium stibogluconate: myocardial, electrophysiological and biochemical studies. QJM 1994;87:465-72.
75. Sundar S, Jha TK, Thakur CP et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 2002;347:1739-46.
76. Guerin PJ, Olliaro P, Sundar S et al. Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2002;2:494-501.
77. Rosenthal E, Marty P, del Giudice P et al. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Infect Dis 2000;31:1093-5.
78. Davidson RN, Russo R. Relapse of visceral leishmaniasis in patients who were coinfected with human immunodeficiency virus and who received treatment with liposomal amphotericin B. Clin Infect Dis 1994;19:560.
79. Fernandez Cotarelo MJ, Abellan Martinez J, Guerra Vales JM, Martinez Sanchez P, Rodrigo Gomez De La Barcena M, Salto Fernandez E. Effect of highly active antiretroviral therapy on the incidence and clinical manifestations of visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 2003;37:973-7.